GREY:ATBPF - Post by User
Post by
Betteryear2on Nov 01, 2023 10:33am
157 Views
Post# 35711169
Antibe Completes First Clinical Study
Antibe Completes First Clinical Study
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’s safety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar Q1 2024.
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation | Business Wire